Evidence map›Paper›PMID 40196575›Full record

ArticlebioRxiv : the preprint server for biology2025

The spontaneous neoantigen-specific CD4

Ryan Q Griswold, Spencer E Brightman, Karla Soria Zavala, Manuel Azaid Ordaz-Arias, Navid Djassemi, Rukman R Thota, Martin S Naradikian, Hannah Dose, Suzie Alarcon, Vijayanand Pandurangan and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Ryan Q GriswoldCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, California, USA.ORCID 0009-0001-8794-8675
Spencer E BrightmanCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, California, USA.
Karla Soria ZavalaCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, California, USA.
Manuel Azaid Ordaz-AriasDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA.
Navid DjassemiCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, California, USA.
Rukman R ThotaCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, California, USA.
Martin S NaradikianCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, California, USA.
Hannah DoseAUGenomics, San Diego, CA.
Suzie AlarconAUGenomics, San Diego, CA.
Vijayanand PanduranganDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA.
Bjoern PetersDivision of Hematology and Oncology, University of California San Diego Moores Cancer Center, La Jolla, California, USA.
Aaron M MillerCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, California, USA.
Ezra E W CohenDivision of Hematology and Oncology, University of California San Diego Moores Cancer Center, La Jolla, California, USA.
Stephen P SchoenbergerCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, California, USA.

Funding

Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6M
NIDCR NIH HHS U01 DE028227
6 · The paper itself

Abstract

CD4

Identifiers

PMID40196575
PMCPMC11974889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.